Anika Therapeutics (ANIK) Liabilities from Discontinued Operations (2023 - 2024)
Anika Therapeutics' (ANIK) quarterly Liabilities from Discontinued Operations came in at $4.1 million in Q4 2024, down 61.83% year-over-year from $10.8 million in Q1 2024, and down 61.83% quarter-over-quarter from $10.8 million in Q4 2023.
Powered by 
Analysis
Anika Therapeutics (ANIK) Liabilities from Discontinued Operations (2023 - 2024) Analysis & Trends
Anika Therapeutics (ANIK) has reported Liabilities from Discontinued Operations for 2 consecutive years, with $4.1 million the latest figure, recorded in Q4 2024.
- On a quarterly basis, Liabilities from Discontinued Operations fell 61.83% year-over-year to $4.1 million in Q4 2024; TTM through Dec 2024 was $4.1 million, a 61.83% decrease from a year earlier, with the FY2024 full-year figure at $4.1 million, down 61.83% from the prior year.
- Liabilities from Discontinued Operations was $4.1 million for Q4 2024 at Anika Therapeutics, down from $10.8 million in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at $10.8 million in Q4 2023 and troughed at $4.1 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | Anika Therapeutics | 277.93 Mn | 239.52 Mn | 21.24 Mn |